{"id":771085,"date":"2019-04-16T16:36:49","date_gmt":"2019-04-16T13:36:49","guid":{"rendered":""},"modified":"2019-04-16T16:40:38","modified_gmt":"2019-04-16T13:40:38","slug":"takeda-zavershyla-protses-prydbannya-shire","status":"publish","type":"post","link":"https:\/\/new.eba.com.ua\/en\/takeda-zavershyla-protses-prydbannya-shire\/","title":{"rendered":"Takeda has Completed its Acquisition of Shire"},"content":{"rendered":"

\"\"<\/p>\n

Takeda (Takeda Pharmaceutical Company Limited) announced the acquisition of Shire (Shire plc) at the beginning of the year. This step has accelerated the transformation of Takeda into a global, values-based, R&D-driven biopharmaceutical company that has expanded its geographic footprint and taken leading position in Japan and the U.S<\/strong>.<\/p>\n

Nowadays the company brings its highly-innovative medicines to patients in approximately 80 countries. Takeda\u2019s R&D efforts are focused on its four therapeutic areas of Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. The company also makes targeted R&D investments in Plasma-Derived Therapies (PDT) and Vaccines. Takeda’s strengthened highly-innovative R&D engine enables the company to develop a more global, robust and modality-diverse pipeline, as well as to focus on breakthrough innovation. The combined annual revenue of the company exceeds $30 billion USD.<\/p>\n

Christophe Weber, President and Chief Executive Officer of Takeda, says that integration of two companies into one is almost complete. The Operating Model, established in September 2018, has set a clear framework for Takeda\u2019s integration plans. The company\u2019s management team is confident that Takeda will retain its investment grade credit rating and will return to a net debt to EBITDA ratio of 2.0 within three to five years following completion.<\/p>\n","protected":false},"excerpt":{"rendered":"

Takeda (Takeda Pharmaceutical Company Limited) announced the acquisition of Shire (Shire plc) at the beginning of the year. This step has accelerated the transformation of Takeda into a global, values-based, R&D-driven biopharmaceutical company that has expanded its geographic footprint and taken leading position in Japan and the U.S. Nowadays the company brings its highly-innovative medicines […]<\/p>\n","protected":false},"author":4489,"featured_media":177071,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[15576,15575],"tags":[],"class_list":["post-771085","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-and-articles-en","category-news-and-articles-from-companies-en","company-16558"],"_links":{"self":[{"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/posts\/771085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/users\/4489"}],"replies":[{"embeddable":true,"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/comments?post=771085"}],"version-history":[{"count":0,"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/posts\/771085\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/media\/177071"}],"wp:attachment":[{"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/media?parent=771085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/categories?post=771085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.eba.com.ua\/en\/wp-json\/wp\/v2\/tags?post=771085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}